HTR1D: A Potential Drug Target for Psychiatric Disorders (G3352)

Target Name: HTR1D

NCBI ID: G3352

HTR1D

HTR1D: A Potential Drug Target for Psychiatric Disorders

HTR1D (5HT1D_HUMAN), a highly conserved G protein-coupled receptor (GPCR), is a potential drug target and biomarker for various psychiatric and neurological disorders. HTR1D is a member of the 5-HT receptor family, which includes other well-known drugs such as SSRIs (e.g., fluoxetine) and dissociative antidepressants (e.g., ketamine).

HTR1D is a transmembrane receptor, meaning that it spans the cell membrane and is associated with various intracellular signaling pathways. The HTR1D receptor is composed of an extracellular portion, a transmembrane segment, and an intracellular segment. The transmembrane segment consists of a catalytic 伪-helices and a carboxylic acid residue, while the intracellular segment is responsible for the interaction with intracellular signaling pathways.

HTR1D is expressed in various tissues and cell types, including brain, heart, pancreas, and gastrointestinal tract. It is involved in various physiological processes, including pain perception, anxiety, and mood regulation.

HTR1D has been implicated in the development and progression of various psychiatric and neurological disorders. For example, HTR1D has been linked to the development of depression, anxiety, and panic disorder. Studies have shown that individuals with major depressive disorder (MDD) have lower levels of HTR1D than healthy individuals. Additionally, individuals with anxiety disorder have higher levels of HTR1D than healthy individuals.

HTR1D has also been shown to play a role in the treatment of psychiatric and neurological disorders. For example, SSRIs, which are commonly used to treat depression and anxiety, work by increasing the levels of HTR1D. Additionally, drugs such as ketamine have been shown to rapidly increase the levels of HTR1D in the brain and improve treatment outcomes in individuals with MDD.

Despite the potential benefits of HTR1D as a drug target, there are also concerns about its potential drawbacks. For example, HTR1D is known to be involved in pain perception and may contribute to the development of chronic pain. Additionally, HTR1D has been shown to interact with other drugs, such as opioids, and may increase the risk of drug abuse.

In conclusion, HTR1D is a promising drug target and biomarker for various psychiatric and neurological disorders. The potential benefits of HTR1D as a drug target make it an attractive target for drug development. However, further research is needed to fully understand the potential risks and benefits of HTR1D as a drug.

Protein Name: 5-hydroxytryptamine Receptor 1D

Functions: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction

The "HTR1D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HTR1D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets